Market Place
Sourcing Support
ChemomAb Therapeutics Announces 2025 Year-End and Q4 Results
19 Mar 2026 //
GLOBENEWSWIRE
AJG Publishes Chemomab`s Nebokitug Phase 2 SPRING PSC Trial
02 Dec 2025 //
GLOBENEWSWIRE
Chemomab Therapeutics Reports Q3 2025 Results and Corporate
20 Nov 2025 //
GLOBENEWSWIRE
Chemomab Presents Nebokitug Ph 2 Trial Data At AASLD
06 Nov 2025 //
GLOBENEWSWIRE
Chemomab Therapeutics at H.C. Wainwright 27th Global Conference
21 Aug 2025 //
GLOBENEWSWIRE
Chemomab Therapeutics Reports Q2 2025 Financials, Updates
14 Aug 2025 //
GLOBENEWSWIRE
Chemomab Reports Positive FDA Meetings for Nebokitug Phase 3
11 Jun 2025 //
GLOBENEWSWIRE
Chemomab gets new patents for Nebokitug, potential PSC drug
03 Jun 2025 //
GLOBENEWSWIRE
Chemomab Therapeutics Announces Q1 2025 Results & Update
15 May 2025 //
GLOBENEWSWIRE
Chemomab Reports Positive Data Supporting Nebokitug at EASL 2025
28 Apr 2025 //
GLOBENEWSWIRE
Chemomab to Present Nebokitug Data at Scientific Conferences
21 Apr 2025 //
GLOBENEWSWIRE
Chemomab Announces New Medical and Clinical Appointments
15 Apr 2025 //
GLOBENEWSWIRE
Chemomab Report Results in Nebokitug Ph 2 PSC Label Extension Trial
27 Mar 2025 //
GLOBENEWSWIRE
Chemomab Reports Q4 & FY24 Results, Provides Corporate Update
03 Mar 2025 //
GLOBENEWSWIRE
Chemomab Aligns With FDA On Ph 3 Path For Nebokitug In PSC
19 Feb 2025 //
GLOBENEWSWIRE
Chemomab to Participate in Oppenheimer Annual Healthcare Conference
03 Feb 2025 //
GLOBENEWSWIRE
Chemomab`s CM-101 Shows Activity in Primary Sclerosing Cholangitis
19 Nov 2024 //
GLOBENEWSWIRE
Chemomab Reports Q3 2024 Results & Corporate Update
14 Nov 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Report Q3 2024 Results & Update
30 Oct 2024 //
GLOBENEWSWIRE
Chemomab Announces Presentation Of Ph 2 Results At AASLD Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Present at Oct 2024 Investor Conferences
01 Oct 2024 //
GLOBENEWSWIRE
Chemomab Therapeutics to Present at September 2024 Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Chemomab Reports Q2 2024 Results And Provides Corporate Update
21 Aug 2024 //
GLOBENEWSWIRE
Chemomab To Report Q2 2024 Results And Provide Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Chemomab Announces New Publications On CM-101 For Sclerosing Cholangitis
18 Jun 2024 //
GLOBENEWSWIRE
Chemomab Presents Data On CM-101 For PSC At EASL 2024 And GRC
06 Jun 2024 //
GLOBENEWSWIRE
Chemomab Awarded New Patents for CM-101
20 Feb 2024 //
PR NEWSWIRE
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Trial
03 Jan 2024 //
PR NEWSWIRE
Chemomab Presents Data for CM-101`s Anti-Fibrotic/Anti-Inflammatory Activity
13 Nov 2023 //
PRESS RELEASE
Chemomab changes CEOs; Ex-FDA vaccine official lends help to Mesoblast
09 Jun 2023 //
ENDPTS
